BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36631812)

  • 1. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
    Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
    J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of HER2 expression using
    Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
    Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
    Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
    Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
    [No Abstract]   [Full Text] [Related]  

  • 4. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical evaluation of
    Bragina O; Chernov V; Larkina M; Rybina A; Zelchan R; Garbukov E; Oroujeni M; Loftenius A; Orlova A; Sörensen J; Frejd FY; Tolmachev V
    Theranostics; 2023; 13(14):4858-4871. PubMed ID: 37771776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe
    Wu Y; Li L; Wang Z; Shi J; Hu Z; Gao S; Miao W; Ma Q; Dong C; Wang F
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2613-2623. PubMed ID: 32170344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Zheng S; Chen Z; Huang C; Chen Y; Miao W
    Ann Nucl Med; 2019 Feb; 33(2):135-143. PubMed ID: 30392070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of [
    Chen Z; Fu F; Li F; Zhu Z; Yang Y; Chen X; Jia B; Zheng S; Huang C; Miao W
    Mol Imaging Biol; 2018 Oct; 20(5):846-856. PubMed ID: 29497956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Xiao L; Yu S; Xu W; Sun Y; Xin J
    Korean J Radiol; 2023 Nov; 24(11):1142-1150. PubMed ID: 37899523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a
    Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
    Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.
    Ji S; Zheng Y; Shao G; Zhou Y; Liu S
    Theranostics; 2013; 3(11):816-30. PubMed ID: 24312152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Preliminary Study of
    Ma M; Yang G; Zhao M; Liu Y; Ge X; Jia B; Gao S
    Mol Pharm; 2024 Feb; 21(2):735-744. PubMed ID: 38193393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
    Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
    Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Shi L; Chen B; Liu T; Li L; Hu B; Li C; Jia B; Wang F
    Mol Pharm; 2022 Jul; 19(7):2583-2594. PubMed ID: 35696536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of
    Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
    Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Imaging of HER2 Expression in Breast Cancer patients Using the [
    Biabani Ardakani J; Abedi SM; Mardanshahi A; Shojaee L; Zaboli E; Khorramimoghaddam A; Nosrati A; Sabahno H; Banimostafavi ES; Hosseinimehr SJ
    Clin Breast Cancer; 2023 Feb; 23(2):219-230. PubMed ID: 36581518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.